

FP1274 TREATMENT OF RECALCITRANT BENIGN SOLAR LENTIGO WITH IMIQUIMOD

M. Casals¹, M. Carrasco², A. Campoy¹, F. Aspiolea¹, A. Camps¹

¹Dermatology, ²Pathology, Hospital General de Catalunya, Sant Cugat, Spain

Solar lentigo is a common sun-induced benign melanocytic proliferation that presents a significant cosmetic worrying for many middle-aged and elderly patients. Imiquimod, a topical immunomodulator that stimulates both acquired and innate immunity, has demonstrated effectiveness in the treatment of lentigo maligna in several small studies. We report the case of a 55-year-old white female with a solar lentigo in the right cheek, previously treated with two sessions of cryotherapy with poor result. After a second relapse she came to our clinic showing a worrisome appearance. With the clinical diagnosis of lentigo maligna we performed two 3-mm punch biopsies of different sites of the lesion. Histology was compatible with benign solar lentigo. Even with the histological diagnosis, we decided to treat the patient with 5 % imiquimod cream, applied to the affected area three times a week for six weeks, with an excellent therapeutic and cosmetic response. As well as with some selected cases of lentigo maligna, we propose 5 % imiquimod cream in the treatment of difficult benign solar lentigo.

References: 1. Spenny ML, Walford J, Werchniak AE et al. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5 % : 12 case reports. *Cutis* 2007;79:149-152.

2. Martín T, Ojeda A, Martínez S, Vera A. Lentigo maligna treated with 5 % imiquimod cream. *Actas Dermosifiliogr* 2005;96:700-702.